Comparison of the Mean Duration of 3rd Stage of Labour Between Intraumbilical and Intravenous Oxytocin

RESnTEC, Institute of Research

Status: Completed

Conditions: Labor

Treatments: Drug: Intravenous oxytocin; Drug: Intraumbilical oxytocin

Study type: Interventional

Funder types: Other

Identifiers

NCT07053930

DRANAMJAVED

Details and patient eligibility

About

There is always a debate for choosing the best method for management of the third stage of labour (TSL) in the general practice for reducing the duration of TSL. Although intravenous oxytocin is more extensively used in general practice for managing TSL than intraumbilical, it still needs to be properly investigated among local populations and in local settings.

Full description

The findings of this study could identify the better route of oxytocin injection that could guide clinicians and health providers to opt for the better route in their routine practice for the management of TSL in order to reduce the morbidity and mortality of the patients, especially for developing countries like Pakistan, where most of the deliveries are conducted at peripheral or rural centers by a nurse, midwife, or a trained dai.

Enrollment: 100 patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Females aged 18-40 years
• With spontaneous vaginal delivery
• Singleton pregnancy
• Gestational age >37 weeks
• Parity l-5
• Any gravidity

Exclusion criteria

• Females with intrauterine fetal death
• Malpresentation
• Multiple pregnancy
• Polyhydramnios
• Premature rupture of membranes
• Medical disorders and hypertensive disorders of pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Intraumbilical oxytocin group

Experimental group

Description:

Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.

Treatment:

Drug: Intraumbilical oxytocin

Intravenous oxytocin group

Experimental group

Description:

Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.

Treatment:

Drug: Intravenous oxytocin